Interpreting MELATORCH Trial Outcomes: PD-1 Inhibitor Toripalimab vs Dacarbazine in First-Line A
09 Apr 20264 min read0 viewsJournal Feed
GIST (Key Takeaways)
To the Editor Recently, Sheng et al published the MELATORCH phase 3 trial, which provided key data comparing the efficacy of the programmed cell death 1 (PD-1) inhibitor toripalimab vs the chemotherapy drug dacarbazine in first-line treatment of advanced acral melanoma.
I appreciate the effort to include a specific population in this study.
To interpret the efficacy more carefully, I will discuss the following 3 issues.
Clinical Editorial
JAMA Oncology published a clinical update in Oncology on 09 Apr 2026.
The item focuses on Challenges in Interpreting MELATORCH Trial Outcomes.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.